Diversified Trust Co Raises Holdings in Amgen Inc. (NASDAQ:AMGN)

Diversified Trust Co raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 16.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 36,855 shares of the medical research company’s stock after acquiring an additional 5,126 shares during the period. Diversified Trust Co’s holdings in Amgen were worth $9,606,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Lantz Financial LLC lifted its holdings in shares of Amgen by 5.1% during the 2nd quarter. Lantz Financial LLC now owns 1,779 shares of the medical research company’s stock valued at $556,000 after acquiring an additional 87 shares in the last quarter. Strategic Financial Concepts LLC acquired a new position in shares of Amgen during the second quarter worth about $26,000. Certuity LLC lifted its stake in shares of Amgen by 72.7% during the second quarter. Certuity LLC now owns 2,249 shares of the medical research company’s stock worth $703,000 after purchasing an additional 947 shares in the last quarter. HCR Wealth Advisors boosted its position in shares of Amgen by 3.3% in the second quarter. HCR Wealth Advisors now owns 4,761 shares of the medical research company’s stock worth $1,488,000 after buying an additional 152 shares during the period. Finally, Ashton Thomas Private Wealth LLC grew its stake in shares of Amgen by 2.5% in the second quarter. Ashton Thomas Private Wealth LLC now owns 83,206 shares of the medical research company’s stock valued at $25,998,000 after buying an additional 2,065 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

AMGN traded up $4.51 during trading on Tuesday, reaching $263.10. 742,272 shares of the company were exchanged, compared to its average volume of 2,665,625. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The firm has a 50 day moving average of $283.46 and a 200 day moving average of $310.11. The stock has a market cap of $141.42 billion, a P/E ratio of 33.69, a PEG ratio of 2.91 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter last year, the company earned $4.96 EPS. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, sell-side analysts forecast that Amgen Inc. will post 19.53 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.62%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is 121.90%.

Analyst Ratings Changes

A number of equities analysts have weighed in on AMGN shares. William Blair restated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Citigroup lowered their price target on shares of Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. Robert W. Baird reiterated an “underperform” rating and issued a $215.00 price objective on shares of Amgen in a report on Wednesday, September 25th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $318.83.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.